Prediction of thyroidal (131)I effective half-life in patients with Graves' disease.

Related Articles

Prediction of thyroidal (131)I effective half-life in patients with Graves' disease.

Oncotarget. 2017 Oct 06;8(46):80934-80940

Authors: Zhang R, Zhang G, Wang R, Tan J, He Y, Meng Z

Abstract
Purpose: Calculation of effective thyroidal half-life (Teff) of iodine-131((131)I) is cumbersome and tedious. The aim of this study was to investigate factors that could be used to predict Teff and to develop a Teff prediction model in Graves' disease patients.
Methods: A total of 256 patients with GD were involved in this study. We investigated the influences of age, gender, disease duration, thyroid weight, antithyroid drugs, antithyroid drugs discontinuation period (ADP), thyroid function indexes, thyroid autoantibodies, thyroid-stimulating hormone receptor antibody (TRAb) level and radioactive iodine uptake (RAIU) values before (131)I therapy on Teff, applying univariate and multivariate analyses.
Results: Teff correlated negatively with thyroid peroxidase antibody, TRAb and thyroid weight, as well as positively with 24-hour, 48-hour, and 72-hour RAIU. Additionally, a longer ADP (especially≥ 14d) or without antithyroid drugs before (131)I therapy led to a longer Teff. Stepwise multiple linear regression analysis showed that 24-hour and 72-hour RAIU were statistically significant predictors of Teff (P<0.001). The relationship was: predictive Teff=5.277+0.295×72-hour RAIU-0.217×24-hour RAIU (r =0.865, P < 0.001).
Conclusion: The present results indicate that prediction of Teff from 24-hour and 72-hour RAIU is feasible in patients with Graves' disease, with high prediction accuracy.

PMID: 29113356 [PubMed]

from Imaging via alkiviadis.1961 on Inoreader http://ift.tt/2yKnzHm